Stock Ratings / Health Care / PRTA / earnings

KMDA (49) MNPR (27) BLSM (42) FTH (29) ⌘ Pro Terminal →

Prothena Corporation plc (PRTA) Next Earnings Date & Expected ±11.1% Move

$8.88 -2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.82

Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $455.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRTA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $8.88 (-2.42% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #937 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRTA compare to KMDA and MNPR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KMDA (Kamada Ltd.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $458.8M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, PRTA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRTA?

▼

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.82 (-0.63%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11.1%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY PRTA SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (35% of score)

20D Institutional Volume Accumulation (±11.1% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 54.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.43+0.6% Next Q

Q2 (-2Q)

Grade E$8.48-0.9% Next Q

Q3 (-1Q)

Grade E$8.40+5.7% Next Q

Current

Grade E$8.88-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRTA currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.75) and Max Pain ($9.32) forces dealer call-delta covering toward $12.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±11.1% Swing Band

±$0.99 Expected Swing

MODEL EARNINGS SETUP GAUGE

PRTA Quantitative Pre-Earnings Setup: 26/100

Trailing EPS: $4.25 • YoY Revenue Growth: -65%

Model Bullish Setup (26/100)Model Risk Weight (74/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$9.7M	-$244.1M	-$163.6M	52%
FY 2024	2024-12-31	$135.2M	-$122.3M	-$150.1M	52%
FY 2023	2023-12-31	$91.4M	-$147.0M	-$133.9M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)

✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.70%▼ DESCENDING CHANNEL

2026-11-02O $9.10H $9.10L $8.88C $8.88VOL 370.1K

RES: $9.23SUP: $7.71SMA50: $8.75SMA200: $9.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRTA Butterfly Map → + Track PRTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)

Health Care Rank #937 of 1016 ⚔️ KMDA vs PRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRTA vs. KMDA, MNPR, BLSM, FTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #937 by composite RQD confidence (26/100, grade E) and #465 by equity capitalization ($455.9M). Within this direct 5-issuer industry benchmark cohort, PRTA leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. KMDA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PRTA at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRTA ACTIVE Prothena Corporation plc	E	26/100	—	—	-35.0%	-2.42%	$455.9M	Benchmark Subject
KMDA Kamada Ltd.	D	49/100	—	—	—	-0.62%	$458.8M	/kmda-vs-prta →
MNPR Monopar Therapeutics Inc.	E	27/100	—	—	-17.4%	-2.02%	$482.7M	/mnpr-vs-prta →
BLSM BlossomHill Therapeutics Inc.	D-	42/100	—	—	—	-7.59%	$483.4M	/blsm-vs-prta →
FTH Faeth Therapeutics Inc.	E	29/100	—	—	-35.0%	-2.34%	$484.5M	/fth-vs-prta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.7M	-$244.1M	-$163.6M	-$163.6M	$326.8M	—
FY2024 (FY)	2024-12-31	$135.2M	-$122.3M	-$150.1M	-$150.1M	$547.1M	—
FY2023 (FY)	2023-12-31	$91.4M	-$147.0M	-$133.9M	-$133.9M	—	—

3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRTA compare to KMDA and MNPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRTA?

Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRTA last traded at $8.88 (-2.42% on volume of 370,119 shares), positioning the stock +1.49% above its 50-day simple moving average ($8.75) and -3.90% below its 200-day simple moving average ($9.24). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 28.3% percentile with a 14-day RSI of 54.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($7.89 to $9.87).